New research indicates that individuals who stop using new weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt traditional diet and exercise plans.
Research printed in a leading health publication shows that while overweight people frequently drop about a fifth of their body weight while using the jabs, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"Users using these treatments need to be aware of the risk of quick rebound weight gain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to pre-treatment mass in about one and a half years.
Comparing Treatments
The research, which examined dozens of studies involving over 9,000 of patients, contrasted the results of GLP-1 agonists with older methods.
The team point out that individuals who shed pounds through diet and exercise usually see a more gradual creep back—around 100 grams monthly—after stopping.
The Reason for the Fast Regain
Doctors propose the way of the injections is key to understanding the heightened rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Issue?
Health authorities advise the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals contend that, considering the significant potential of weight regain, the treatment might need to be ongoing.
This opinion is echoed by pharmaceutical companies, who say that the findings "emphasize the chronic nature of obesity," similar to managing conditions like diabetes.
Patient Testimonies
Individuals who have stopped the jabs report a intense return of appetite.
"I experienced a switch flipping and you become ravenous," recalled an individual.
This challenge is worsened if patients have not established lasting lifestyle or habit modifications during therapy.
Growing Interest
Figures indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among women than men.
- The middle-aged age group shows the highest usage rates.
- Many access the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while the jabs are potent agents for weight loss, they are not a standalone solution and maintained weight loss hinges on ongoing behavioural support.
